Balofloxacinの呼吸器感染症に対する臨床的有用性の検討

• 沖本 二郎

  川崎医科大学呼吸器内科

• 窪田 好史

  川崎医科大学呼吸器内科

• 宮下 修行

  川崎医科大学呼吸器内科

• 吉田 耕一郎

  川崎医科大学呼吸器内科

• 中島 正光

  川崎医科大学呼吸器内科

• 二木 芳人

  川崎医科大学呼吸器内科

• 副島 林造

  川崎医科大学呼吸器内科

書誌事項

タイトル別名

• Clinical study of balofloxacin in respiratory tract infections

抄録

We performed bacteriological and clinical studies on balofloxacin (BLFX), a new quinolone derivative, in respiratory tract infections and obtained the following results.<BR>1) The MICs of balofloxacin against methicillin-susceptible Staphylococcus aureus (MSSA), Streptococcus pneumoniae, Haemophilus influenzae, Branhamella catarrhalis and Klebsiella pneumoniae ranged from 0.01 to 4μg/ml, equal to those of sparfloxacin (SPFX) and levofloxacin (LVFX). The MIC₉₀ against methicillin-resistant S. aureus (MRSA) was 4μg/ml, which was superior to those of SPFX and LVFX. The MIC₉₀ against Pseudomonas aeruginosa was 64μg/ml, inferior to those of SPFX and LVFX.<BR>2) The MICs against Chlamydia pneumoniae, Chlamydia psittaci and Chlamydia trachomatis were 0.25-0.5μg/ml, equal to those of ofloxacin and ciprofloxacin but inferior to those of tosufloxacin and SPFX.<BR>3) Ten patients with respiratory tract infection were treated with BLFX. Efficacy was rated as excellent in 2, good in 7, and poor in 1 case. The overall clinical efficacy was 90%. No adverse side effects were seen, but there was 1 patient with mild liver dysfunction.

収録刊行物

• 日本化学療法学会雑誌

  日本化学療法学会雑誌 43 (Supplement5), 242-246, 1995

  公益社団法人 日本化学療法学会

キーワード

• ニューキノロン
• 呼吸器感染症

詳細情報

• CRID: 1390282681265213312
• NII論文ID: 10005468659
• NII論文ID: 130004297444
• NII書誌ID: AN10472127
• DOI: 10.11250/chemotherapy1995.43.supplement5_242
• ISSN: 18845886
• ISSN: 13407007
• Web Site: https://search.jamas.or.jp/link/ui/1996067191
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可